Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy
(ACT) have revolutionized cancer treatment, especially in patients whose disease was …

The past decade has witnessed the accelerating development of immunotherapies for
cancer treatment. Immune checkpoint blockade therapies and chimeric antigen receptor …

The tumor immunosuppressive microenvironment greatly limits the efficacy of
immunotherapy. Tumor-associated macrophages (TAMs) are the most abundant …

Despite its intrinsic ability to regenerate form and function after injury, bone tissue can be
challenged by a multitude of pathological conditions. While innovative approaches have …

Despite recent advances in melanoma treatment through the use of anti-PD-1 (aPD1)
immunotherapy, the efficacy of this method remains to be improved. Here we report an …

Although anti-PD-1 immunotherapy is widely used to treat melanoma, its efficacy still has to
be improved. In this work, we present a therapeutic method that combines immunotherapy …

Inflammation-triggered combination delivery of anti-PD-1 antibody (aPD1) and CpG
oligodeoxynucleotides (CpG ODNs) has been demonstrated to prevent cancer relapse …

Cancer cells resist to the host immune antitumor response via multiple suppressive
mechanisms, including the overexpression of PD‐L1 that exhausts antigen‐specific CD8+ T …

Despite the promising efficacy of immunoregulation in cancer therapy, the clinical benefit
has been restricted by inefficient infiltration of lymphocytes in the evolution of immune …

Cancer immunotherapy, as a paradigm shift in cancer treatment, has recently received
tremendous attention. The active cancer vaccination, immune checkpoint blockage (ICB) …